Sanofi Receives EU Conditional Marketing Authorization For Rezurock In Chronic GVHD

The European Commission granted conditional marketing authorization for Sanofi's Rezurock to treat chronic graft‑versus‑host disease in adults and in children aged 12+ with body weight ≥40 kg. The authorization allows EU commercialization subject to post‑authorization conditions and should provide a modest revenue and patient‑access boost for Sanofi. This regulatory win is likely to move Sanofi shares modestly (roughly 1‑3%).

Analysis

The European Commission granted conditional marketing authorization for Sanofi's Rezurock to treat chronic graft‑versus‑host disease in adults and in children aged 12+ with body weight ≥40 kg. The authorization allows EU commercialization subject to post‑authorization conditions and should provide a modest revenue and patient‑access boost for Sanofi. This regulatory win is likely to move Sanofi shares modestly (roughly 1‑3%).